Product Information
EPINEPHRINE 1 MG/10 ML ABBOJCT is a generic product labeled by Hospira Inc., priced at $1.1940 per ML under NDC 00409493310. Its NADAC has been published 52 times since May 28, 2025.
FDA first approved this application on Nov 5, 2019.
Strength
.1 mg/mL
Manufacturer
Hospira Inc.NDC
00409493310
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
5/20/2026
Active Ingredients
EPINEPHRINEApproval Type
New Drug (NDA)
FDA Application
NDA209359FDA Approved
11/5/2019
On Market Since
3/10/2021
Pharmacological Classes
Price Statistics
The NADAC for EPINEPHRINE 1 MG/10 ML ABBOJCT has been published 52 times since May 28, 2025, and over the history we have for it it has risen 8.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1940 per ML |
|---|---|
| All-time high | $1.2110 (Dec 10, 2025) |
| All-time low | $1.1001 (May 28, 2025) |
| 52-week high | $1.2110 |
| 52-week low | $1.1650 |
| Median price | $1.1936 |
| Average price | $1.1714 |
| Largest weekly change | +2.5% (Oct 22, 2025) |
| Weeks tracked | 52 |
| Tracking since | May 28, 2025 |
1W
N/A
1M
N/A
3M
N/A
6M
-0.7%
1Y
+2.5%
3Y
N/A
5Y
N/A
All
+8.5%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the epinephrine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
epinephrine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Catecholamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EPINEPHRINE 1 MG/10 ML ABBOJCT?
The current National Average Drug Acquisition Cost (NADAC) for EPINEPHRINE 1 MG/10 ML ABBOJCT, manufactured by Hospira Inc., is $1.1940 per ML (NDC 00409493310), effective May 20, 2026.
How has the price of EPINEPHRINE 1 MG/10 ML ABBOJCT changed over time?
Over the history we have for it, the NADAC for EPINEPHRINE 1 MG/10 ML ABBOJCT has risen 8.5%. It has been tracked across 52 weekly CMS publications since May 28, 2025.
What are the highest and lowest recorded NADAC prices for EPINEPHRINE 1 MG/10 ML ABBOJCT?
Since May 28, 2025, the NADAC for EPINEPHRINE 1 MG/10 ML ABBOJCT has ranged from a low of $1.1001 (May 28, 2025) to a high of $1.2110 (Dec 10, 2025), with a median of $1.1936 per ML.
Are there cheaper alternatives to EPINEPHRINE 1 MG/10 ML ABBOJCT?
No other NADAC-published product currently shares the active ingredient and strength of EPINEPHRINE 1 MG/10 ML ABBOJCT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EPINEPHRINE 1 MG/10 ML ABBOJCT?
EPINEPHRINE 1 MG/10 ML ABBOJCT (NDC 00409493310) is labeled by Hospira Inc., and CMS classifies it as a generic product.